Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc is advancing its product candidate, lorundrostat, which has demonstrated a significant potential to improve blood pressure management, showing a placebo-adjusted benefit of over 10mmHg, a key metric that resonates positively with prescribers. The company's robust profile in addressing uncontrolled and resistant hypertension, along with anticipated FDA feedback and a near-term NDA submission, suggests promising commercial prospects. Additionally, feedback from key opinion leaders (KOLs) indicates a growing patient need for innovative treatments, leading to an increase in estimated market uptake from 10% to 12% among patients diagnosed with uncontrolled hypertension.

Bears say

The financial outlook for Mineralys Therapeutics Inc. remains negative due to several significant risks, including the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates influenced by market size, penetration rates, and pricing challenges. Additionally, the company faces the risk of inadequate capital resources necessary to fund its operations, which could hinder continued program development and commercialization efforts. Concerns surrounding patient safety, particularly regarding potassium levels and the implications of potential regulatory cutoff adjustments, further exacerbate the company's investment risks.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.